ARTICLE | Top Story
GSK, HGSI diabetes deal
October 26, 2004 7:00 AM UTC
GlaxoSmithKline (LSE:GSK; GSK) licensed exclusive worldwide rights from Human Genome Sciences (HGSI) to develop and commercialize Albugon albumin- glucagon-like peptide-1 (GLP-1) to treat diabetes. Th...